Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators

Biochemical Pharmacology

Volumn 51, Issue 11, 1996, Pages 1553-1561

  Renton, Fiona J ^b   Jeitner, Thomas M ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

cell cycle; desferrioxamine; DNA synthesis; iron chelators; neural tumors

Indexed keywords

CHELATING AGENT; DEFEROXAMINE MESYLATE; RAZOXANE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DNA SYNTHESIS; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRON CHELATION; MITOSIS INHIBITION; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0030063939     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00099-8     Document Type: Article

References (55)

1. Voest EE, Vreugdenhil G and Marx JJM, Iron-chelating agents in non-iron overload conditions. Ann Intern Med 120: 490-499, 1994.
2. Blatt J and Stitely S, Antineurohlastoma activity of desferoxamine in human cell lines. Cancer Res 47: 1749-1750, 1987.
3. Becton DL and Bryles P, Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48: 7189-7192, 1988.
4. Skala JP, Rodders PCJ, Chan K-W, Chao HY and Rodriguez WC, Deferoxamine as purging agent for autologous bone marrow grafts in neuroblastoma. In: Advances in Bone Marrow: Purging and Processing (Ed. Skala JP), pp. 71-78. Wiley-Liss, New York, 1992.
5. Estrov Z, Tawa A, Wang X-H, Dubé ID, Sulh H, Cohen A, Gelfand EW and Freedman MH, In vitro and in vivo effects of deteroxamine in neonatal acute leukemia. Blood 69: 757-761, 1987.
6. Wolf L, Leitzel K, Witkoski E, Bartholomew M and Lipton A, Deferoxamme prolongs survival of mice with L1210 lymphocytic leukemia. Proc Am Assoc Cancer Res 29: 2053-2058, 1988.
7. Donfrancesco A, Deb G, Domimci C, Pilleggi D, Castello M and Helson L, Effects ot a single course of deferoxamine in neuroblastoma patients. Cancer Res 50: 4929-4930, 1990.
8. Blatt J, Boegel F, Hedlund BE, Arena VC and Shadduck RK, Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine. Leuk Res 15: 391-394, 1991.
9. Summers MR, Jacobs A, Tudway D and Perera P, Studies in desferrioxamine and ferroxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42: 547-555, 1979.
10. Hoffbrand AV, Ganeshaguru K, Hooton JWL and Tattersall MHN, Effect ot iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 33: 517-526, 1976.
11. Oblender M and Carpentieri U, Growth, ribonucleotide reductase and metals in murine leukemic lymphocytes. J Cancer Res Clin Oncol 17: 444-448, 1991.
12. Hoyes KP, Hider RC and Porter JB, Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res 52: 4591-4599, 1992.
13. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A and Thelander L, Role of ribonucleotide reductase in inhibition of mammalian cell cycle growth by potent iron chelators. J Biol Chem 268: 26200-26205, 1993.
14. Lederman HM, Cohen A, Lee JWW, Freedman MH and Gelfand EW, Deferioxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64: 748-753, 1984.
15. Bergeron RJ and Ingeno MJ, Microbial iron chelator-induced cell cycle synchronization in L1210 cells: Potential in combination chemotherapy. Cancer Res 47: 6010-6016, 1987.
16. Siegers C-P, Bumann D and Baretton G, The effect of desferrioxamine on cell proliferation in human tumor cell lines. Toxicol In Vitro 5: 427-430, 1991.
17. Blatt J, Taylor SR and Stitely S, Mechanism of antineuroblastoma activity of deferoxamine in vitro. J Lab Clin Med 112: 433-436, 1988.
18. Blatt J, Taylor SR and Kontoghiorghes GJ, Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res 49: 2925-2927, 1989.
19. 1 phase of the cell cycle. Cancer Res 53: 3968-3975, 1993.
20. Bomford A, Issac J, Roberts S, Edwards A, Young S and Williams R, The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemia cells. Biochem J 236: 243-249, 1986.
21. Poot M, Rabinovitch PS and Hoehn H, Free radical mediated cytotoxicity of deferoxamine. Free Radic Res Commun 6: 323-328, 1989.
22. Huang ZX, May PM, Quilan KM, Williams DR and Creighton AM, Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis product of the antitumour agent ICRF 159 and its inactive homologue ICRF192. Agents Actions 12: 536-542, 1982.
23. Hasinoff BB, The interaction of the cardioprotective agent ICRF-187 ((±)-1,2-bis(3,5-dioxopiperazine-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes with adriamycin. Agents Actions 26: 378-385, 1989.
24. Sharpe HBA, Field EO and Hellman K, Mode of action of the cytostatic agent 'ICRF 159'. Nature 226: 524-526, 1970.
25. Taylor IW and Bleehen NM, Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Br J Cancer 35: 587-594, 1977.
26. Morris VB and Taylor IW, Estimation of nonproliferating cells in the neural retina of embryonic chicks by flow cytometry. Cytometry 6: 375-380, 1985.
27. van Reyk DM, Sarel S and Hunt NH, In vitro effects of three iron chelators on mitogen-activated lymphocytes: Identification of differences in their mechanisms of action, Int J Immunopharmacol 14: 925-932, 1992.
28. Jacobsen PF, Jenkyn DJ and Papadimitriou JM, Four permanent cell lines established from human malignant gliomas: Three exhibiting striated muscle differentiation. J Neuropathol Exp Neurol 46: 431-450, 1987.
29. Furukawa T, Naitoh Y, Kohno H, Tokunaga R and Taketani S, Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci 50: 2059-2065, 1992.
30. Bollinger JM, Edmondson DE, Hynh BM, Filley J, Norton JR and Stubbe J, Mechanism of assembly of the tyrosyl radicaldinuclear iron cluster cofactor of ribonucleotide reductase. Science 253: 292-298, 1991.
31. Oblender M and Carpentieri U, Effects of iron, copper and zinc on the activity of ribonucleotide reductase in normal leukaemic human lymphocytes. Anticancer Res 10: 123-128, 1990.
32. Becton DL and Roberts B, Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res 49: 4809-4812, 1989.
33. rb phosphorylation during cell cycle progression of normal human T cells. J Immunol 148: 1804-1811, 1992.
34. Dalton S, Cell cycle regulation of the human cdc2 gene. EMBO J 11: 1797-1804, 1992.
35. Terada N, Or R, Szepesi A, Lucas JJ and Gefland EW, Definition of the roles for iron and essential fatty acids in cell cycle progression of normal human T lymphocytes. Exp Cell Res 204: 260-267, 1993.
36. Traganos F, Darzynkiewicz Z and Melamed MR, Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res 41: 4566-4576, 1981.
37. Tabor E and Kim CM, Inhibition of human hepatocellular carcinoma and hepatoblastoma cell lines by deferoxamine. J Med Virol 34: 45-50, 1991.
38. Yung Y-M, Yang YH and Bor AM-S, Nuclear protein B23 translocation after deferoxamine treatment in a human leukaemia cell line. Int J Cancer 48: 779-784, 1991.
39. Bottomley SS, Wolfe LC and Bridges KR, Iron metabolism in K562 erythroleukemic cells. J Biol Chem 260: 6811-6815, 1985.
40. Richardson D, Ponka P and Baker E, The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54: 685-689, 1994.
41. Halliwell B, Superoxide-dependent formation of hydroxyl radicals in the presence of iron chelates. FEBS Lett 92: 321-326, 1978.
42. Klebanoff SJ, Waltersdorph AM, Michel BR and Rosen H, Oxygen-based free radical generation by ferrous ions and deferoxamine. J Biol Chem 264: 19765-19771, 1989.
43. Chan RYY, Ponka P and Schulman HM, Transferrin-receptor-independent but iron-dependent proliferation of variant Chinese hamster ovary cells. Exp Cell Res 202: 326-336, 1992.
44. Voest EE, Rooth H, Neijit JP, van Asbeck BS and Marx JJM, The in vitro response of human tumour cells to desferrioxamine is growth medium dependent. Cell Prolif 26: 77-88, 1993.
45. Chaudhri G, Clark IA, Hunt NH, Cowden WB and Ceredig R, Effect of antioxidants on primary alloantigen-induced T cell activation and proliferation. J Immunol 137: 2646-2656, 1986.
46. Chaudhri G, Hunt NH, Clark IA and Ceredig R, Antioxidants inhibit proliferation and cell surface expression of receptors for interleukin-2 and transferrin in T lymphocytes stimulated with phorbol myristate and ionomycin. Cell Immunol 115: 204-213, 1988.
47. Hunt NH and Fragonas J-C, Effects of anti-oxidants on ornithine decarboxylase in mitogenically-activated T lymphocytes. Biochim Biophys Acta 1133: 261-267, 1992.
48. Young SP and Garner C, Delivery of iron to human cells by bovine transferrin. Biochem J 265: 587-591, 1990.
49. Kemp JD, Thorson JA, Stewart BC and Naumann PW, Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: Evidence for a threshold model of iron deprivation toxicity. Cancer Res 52: 4144-4148, 1992.
50. Kemp JD, Smith KM, Kanner LJ, Gomez F, Thorson JA and Naumann PW, Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76: 991-995, 1990.
51. Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB and Singh S, Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 21: 640-644, 1993.
52. Davies SC, Hungerford JL, Arden GB, Marcus RE, Miller MH and Huehns ER, Ocular toxicicy of high-dose intravenous desferrioxamme. Lancet 2: 181-184, 1983.
53. Gallant T, Boyden MH, Gallant LA, Carley H and Freedman MH, Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med 83: 1085-1090, 1987.
54. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M and Freedman MH, Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314: 869-873, 1986.
55. Tannock IF and Hill RP, The Basic Science of Oncology, 2nd Edn. McGraw-Hill, New York, 1992.